Condition: Metastatic Prostate Cancer · Hormone Sensitive Prostate Cancer · Chemotherapy Effect · Sponsor: The First Affiliated Hospital with Nanjing Medical University
Evaluate whether the combination of Rezvilutamide and androgen deprivation therapy (ADT) with docetaxel improves overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) compared to the combination of Rezvilutamide and ADT.
This description comes directly from the study's public registry record.
Shangqian Wang, M.D., Ph.D. · +862568303186 · wsq5501@126.com
Always discuss trial participation with your own doctor first.
| Urology dpt, First Affiliated Hospital of Nanjing Medical University | Nanjing, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05983783